Latest news with #IDEXX
Yahoo
3 days ago
- Business
- Yahoo
IDEXX Laboratories (NasdaqGS:IDXX) Launches Catalyst Cortisol Test for Canine Health
IDEXX Laboratories recently introduced its Catalyst® Cortisol Test, an advance in veterinary diagnostics, and reported an earnings growth with a raised revenue guidance for 2025. Furthermore, the company repurchased 930,800 shares, indicating strong financial health. These developments likely supported IDEXX's 22% share price increase over the last quarter. Meanwhile, broader market movements were relatively modest, with indices experiencing slight gains amid optimistic trade discussions between the U.S. and China and positive economic data. IDEXX's performance was possibly bolstered by its innovative launches and solid financials, in line with buoyant market sentiments. We've spotted 1 risk for IDEXX Laboratories you should be aware of. Find companies with promising cash flow potential yet trading below their fair value. The introduction of the Catalyst® Cortisol Test and share repurchase strengthens IDEXX Laboratories' position in veterinary diagnostics, potentially boosting revenue and earnings forecasts through increased diagnostic usage and market expansion. Over the past five years, IDEXX's total shareholder returns increased by 63.06%, including price movements and dividends, reflecting consistent long-term growth despite some market volatilities. In contrast, IDEXX underperformed the US Medical Equipment industry over the past year, which returned 9%. Though the current share price increase in the last quarter aligns with recent innovations and improved guidance, it trades close to the consensus price target of US$496.54. This suggests analysts view the company as nearing fair value. However, continued product innovations and strategic international expansions might influence future market valuations as IDEXX strives to enhance revenue and earnings growth amid potential challenges such as trade tensions and changing clinical visits. Our comprehensive valuation report raises the possibility that IDEXX Laboratories is priced higher than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:IDXX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
3 days ago
- Health
- Cision Canada
Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders
WESTBROOK, Maine, June 5, 2025 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst ® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care. Addison's disease, often called "the great pretender," is a life-threatening condition caused by low cortisol and is difficult to diagnose due to its common and nonspecific clinical signs that can resemble those of other illnesses, such as gastroenteritis or kidney disease. Early detection is critical, as timely treatment can be lifesaving. Cushing's syndrome, driven by excess cortisol, is a common endocrine disorder in older dogs, and certain breeds are at an increased risk. Cushing's syndrome requires long-term management, and if left untreated, it can significantly diminish quality of life. IDEXX's Catalyst Cortisol Test enables veterinarians to confidently and accurately diagnose or rule out Addison's disease and Cushing's syndrome during the patient visit, allowing for immediate treatment or adjustments to ongoing care management. This workflow efficiency continues throughout the patient journey with monitoring capabilities that enable tailored treatment adjustments, improving long-term care for patients with Cushing's syndrome. "The Catalyst Cortisol Test is an accurate and highly requested test that addresses a critical need for our customers and equips veterinarians with built-in results interpretation for prompt action, supporting better health outcomes for dogs," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "Continuing to expand the Catalyst platform reinforces our Technology for Life promise, offering our customers solutions that advance in capabilities over time to expand clinical insights and care delivery at the point-of-care." The IDEXX Catalyst Cortisol Test features: Accuracy: Provides quantitative results in-clinic that align with IDEXX Reference Laboratories, enabling veterinarians to confidently diagnose or rule out Addison's disease and Cushing's syndrome. Interpretive guidance: Integrates with the IDEXX Vetlab ® Station and VetConnect ® PLUS, providing results-specific interpretation in real-time during the patient visit. Efficiency: The Catalyst Cortisol Test's load-and-go workflow can run alone or with additional chemistry tests using a single sample for comprehensive diagnostic insights into patient health status. This workflow saves hands-on sample preparation time for veterinary technicians and ensures repeatable results. "A reliable in-house test is game-changing—it enables faster diagnosis and treatment of a life-threatening Addisonian crisis in dogs," said Patty Lathan, VMD, MS, DACVIM (SAIM).* "Additionally, by delivering accurate results during the visit, it supports timely care and streamlines daily workflows for busy veterinary teams." The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025, with a global rollout to the installed base of more than 75,000 Catalyst chemistry analyzers expected to start in the third quarter of 2025. For more information, visit the IDEXX Catalyst test menu web page. About IDEXX IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: Note Regarding Forward-Looking Statements This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at and via IDEXX's website at
CNBC
30-05-2025
- Business
- CNBC
Lightning Round: If you like BigBear.ai buy Palantir, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: D-Wave Quantum, IDEXX, and Biohaven.
Yahoo
19-05-2025
- Business
- Yahoo
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks. What if you'd invested in Idexx Laboratories (IDXX) ten years ago? It may not have been easy to hold on to IDXX for all that time, but if you did, how much would your investment be worth today? With that in mind, let's take a look at Idexx Laboratories' main business drivers. Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics operates through four segments:Companion Animal Group (CAG) (91.7% of revenues in 2024, up 1.0% from 2023): This segment provides veterinarians with diagnostic capabilities and information management solutions that enhance the health and well-being of pets. The complementary nature of these products and services provides a unique competitive advantage known as the IDEXX Diagnostic Advantage, providing vets with the tools and services necessary to offer advanced veterinary medical (4.7%, up 2.2%): Through this segment, IDEXX provides innovative testing solutions for easy, rapid and accurate detection and quantification of various microbiological parameters in water, helping ensure water safety for people Poultry and Dairy (LPD) (3.1%, down 6.0%): Within this segment, IDEXX provides diagnostic tests and related instrumentation required to manage the health status of livestock and poultry to improve bovine reproductive efficiency and ensure the quality and safety of milk and food. These products are purchased by the government and private laboratories that provide testing services to cattle, swine and poultry veterinarians, producers and (0.4%, down 20.0%): The company's OPTI Medical operating segment has been combined and presented with the remaining pharmaceutical product line and the out-licensing arrangements in an 'Other' category, primarily because they do not meet the quantitative or qualitative thresholds for reportable segments. While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Idexx Laboratories ten years ago, you're probably feeling pretty good about your investment today. According to our calculations, a $1000 investment made in May 2015 would be worth $7,661.93, or a 666.19% gain, as of May 19, 2025. Investors should keep in mind that this return excludes dividends but includes price appreciation. The S&P 500 rose 180.69% and the price of gold increased 153.90% over the same time frame in comparison. Analysts are anticipating more upside for IDXX. IDEXX's robust strategic execution is highlighted by new business gains, high customer retention levels and solid net price realization. This underscores the consistent growth in the CAG international business, supported by volume gains and global premium instrument placements. The company's software solutions are facilitating growth by enhancing clinic workflows and promoting greater utilization of diagnostics. Also, the consumable business boosts its top line. Meanwhile, IDEXX's debt-burdened balance sheet raises concern. The company's wide global presence makes it vulnerable to currency fluctuations. Meanwhile, broader macroeconomic issues are slowing its operations. The stock has jumped 25.91% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 7 higher, for fiscal 2025; the consensus estimate has moved up as well. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
13-05-2025
- Business
- Business Wire
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on the IDEXX website, An archived edition of the presentation will be available via the same link. 2025 Investor Day IDEXX Laboratories, Inc. also announced today that it will host its 2025 Investor Day on Thursday, August 14, 2025 at its corporate headquarters in Westbrook, Maine from approximately 8:00 am to 12:00 pm (EDT). A live webcast of the presentations will be available on Advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact investorrelations@ Additional information on IDEXX's Investor Day will be provided closer to the date of the event. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 ® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit
